Healthcare Economist May 6, 2024
That is the title of my article with Melanie Whittington and Louis Garrison in STAT News. An excerpt is below:
The changing landscape of drug pricing policy in the U.S. has implications for the global pace and direction of innovation. Drug policy changes are being influenced by perceptions of the value of novel medicines relative to their budgetary impacts, with some believing that many medicines may not be worth their cost, creating an important role for health technology assessments (HTA). The goals of these assessments are to ensure that society does not overpay for new medications, but also does not inadvertently discourage the development of worthwhile medicines and other health technologies.
For years, the U.S. was apparently content to...
Today's Sponsors
Today's Sponsor